Form 4: Director Thompson Acquires CPRX Shares

Catalyst Pharmaceuticals Director Tamar Thompson acquired 1,413 shares of common stock following the vesting of restricted stock units.

Summary

• Tamar Thompson, a Director of Catalyst Pharmaceuticals, Inc. (CPRX), acquired 1,413 shares of the company's common stock.
• This acquisition occurred on December 8, 2025, as a result of the vesting and delivery of the second tranche of her Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of common stock upon vesting.
• The RSUs vested in three equal tranches: December 8, 2024, December 8, 2025, and December 8, 2026.
• Following this transaction, Ms. Thompson directly beneficially owns 3,773 shares of common stock.
• She also continues to beneficially own 119,663 Restricted Stock Units.

Sentiment

Score: 6

Explanation: The transaction is a routine vesting of equity compensation for a director, indicating continued alignment of interests with shareholders. The acquisition of shares by an insider is generally a positive signal, though it's a scheduled event rather than an open market purchase.

Positives

• An insider (Director) is increasing their direct ownership of common stock, which can be seen as a vote of confidence in the company's future.

Future Outlook

The filing does not provide specific forward-looking statements or guidance beyond the scheduled vesting of future Restricted Stock Units.

Industry Context

This Form 4 filing details a routine insider transaction related to equity compensation and does not provide information relevant to broader industry trends or competitive analysis.

Comparison to Industry Standards

• This filing is a standard disclosure of insider stock ownership changes due to equity compensation vesting and does not contain information for comparison to industry-specific operational or financial benchmarks.

Stakeholder Impact

• Shareholders: The acquisition of shares by a director through equity compensation vesting aligns the director's interests with shareholders, potentially signaling confidence in the company's long-term performance.
• Employees: The vesting schedule of RSUs is a common form of long-term incentive compensation, which can motivate and retain key personnel.

Next Steps

• The final tranche of Restricted Stock Units is scheduled to vest on December 8, 2026, which will result in the delivery of additional common stock to the reporting person.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-scheduled vesting and delivery of equity compensation to a director. While insider acquisition of shares is generally a positive signal, this is not an open market purchase and does not provide new fundamental information to warrant a change in investment recommendation. It primarily confirms ongoing alignment of interests.

Keywords

Catalyst Pharmaceuticals, CPRX, Tamar Thompson, Insider Trading, Form 4, Stock Acquisition, Restricted Stock Units, RSU Vesting, Director Stock Ownership